Imagia Canexia Health Achieves First CE-IVD Status in the E.U. to Deploy Comprehensive Cancer Testing Platform

The Imagia Canexia Health Insights Platform (ICHIP), which provides cancer-treatment analysis directly to local oncologists, is now available across Europe

Imagia Canexia Health, a genomics-based cancer treatment testing company that accelerates access to precision care by combining AI expertise with advanced molecular biopsy solutions, announced the CE-IVD marking for its Imagia Canexia Health Insights Platform (ICHIP) to operate across Europe. ICHIP provides intricate molecular and computational genome analysis, from targeted next-generation sequencing (NGS) data, for individual cancer patients. The company offers a unique clinical solution for European oncologists to quickly generate reports—including therapeutic and clinical trial recommendations. This new approval furthers Imagia Canexia Health’s mission to combine advanced genomics, oncology, artificial intelligence, and informatics to enable health systems to provide cost-effective testing in-house—thus delivering precision cancer treatments to patients no matter where they live.

Latest Aithority Insights: AI Company Decide Expands in the US to Lead in the Cookieless World

@ImagiaCanexia achieves first CE-IVD status to deploy comprehensive cancer testing platform across #Europe. This continues their mission to close the #healthequity gap in #cancer.

Clinicians receive next-generation sequencing (NGS) data sourced from human tissue or blood samples. These insights are collected, as well as processed, on Illumina’s NextSeq and MiSeq devices. Then, ICHIP uses AI to detect and analyze genomic variants, match interpretations, identify potential clinical trials, as well as generate a cancer-treatment results report. This creates a new ability to integrate clinical and genomic patient data, augmenting treatment decisions by oncologists. With this crucial information, health professionals can rapidly access data about a cancer patient’s genetics, as well as describe the potential associations between detected variants and specific therapeutics, all while making the most informed care-management decisions.

Read More About Aithority News : Deutsche Telekom Network Monitored By AI Solution from BENOCS and Anodot

“Achieving the CE-IVD mark, a highly regarded standard around the globe, represents an important milestone that reflects the technological quality and rigor upon which we built the Imagia Canexia Health Insights Platform (ICHIP),” said Imagia Canexia Health CEO Geralyn Ochab. “Our company takes pride in the platform’s ability to quickly provide specialists with vital information to fight cancer, now supporting European oncologists with life-saving information for their patients.”

Top Machine Learning Insights: LivePerson Collaborates with UCSC to Build the Future of Natural…

[To share your insights with us, please write to sghosh@martechseries.com]